Neurodegenerative Pathways in Parkinson's Disease: Therapeutic Strategies

被引：44
作者：
Cardoso, S. M. [1 ,2 ]
Moreira, P., I
Agostinho, P.
Pereira, C.
Oliveira, C. R.
机构：
[1] Univ Coimbra, Fac Med Coimbra, Ctr Neurosci & Cell Biol, P-3004504 Coimbra, Portugal
[2] Univ Coimbra, Fac Med Coimbra, Inst Biochem, P-3004504 Coimbra, Portugal
来源：
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS | 2005年 / 4卷 / 04期
关键词：
alpha-synuclein; neuronal circuits; oxidative stress; mitochondria; proteasome; neuroinflammation; cell death; therapeutics;
D O I：
10.2174/1568007054546072
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Parkinson's disease (PD), considered one of the major neurological disorders, is characterized by the loss of dopaminergic neurons in the pars compacta of the substantia nigra and by the presence of intraneuronal cytoplasmic inclusions called Lewy bodies. The causes for degeneration of PD neurons remain unclear, however, recent findings contributed to clarify this issue. This review will discuss the current understanding of the mechanisms underlying Parkinson's disease pathogenesis, focusing on the current and potential therapeutic strategies for human treatment.
引用
收藏
页码：405 / 419
页数：15
相关论文
共 239 条
[21]   Neural transplantation for the treatment of Parkinson's disease [J].
Björklund, A ;
Dunnett, SB ;
Brundin, P ;
Stoessl, AJ ;
Freed, CR ;
Breeze, RE ;
Levivier, M ;
Peschanski, M ;
Studer, L ;
Barker, R .
LANCET NEUROLOGY, 2003, 2 (07) :437-445
[22]   Short-term effects of high-dose 17β-estradiol in postmenopausal PD patients -: A crossover study [J].
Blanchet, PJ ;
Fang, J ;
Hyland, K ;
Arnold, LA ;
Mouradian, MM ;
Chase, TN .
NEUROLOGY, 1999, 53 (01) :91-95
[23]  
Blanchet PJ, 1998, CLIN NEUROPHARMACOL, V21, P339
[24]   Functional changes of the basal ganglia circuitry in Parkinson's disease [J].
Blandini, F ;
Nappi, G ;
Tassorelli, C ;
Martignoni, E .
PROGRESS IN NEUROBIOLOGY, 2000, 62 (01) :63-88
[25]   Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease [J].
Blum, D ;
Torch, S ;
Lambeng, N ;
Nissou, MF ;
Benabid, AL ;
Sadoul, R ;
Verna, JM .
PROGRESS IN NEUROBIOLOGY, 2001, 65 (02) :135-172
[26]   Molecular pathways to neurodegeneration [J].
Bossy-Wetzel, E ;
Schwarzenbacher, R ;
Lipton, SA .
NATURE MEDICINE, 2004, 10 (07) :S2-S9
[27]   DIFFERENTIAL-EFFECTS OF D1 AND D2 AGONISTS IN MPTP-TREATED PRIMATES - FUNCTIONAL IMPLICATIONS FOR PARKINSONS-DISEASE [J].
BOYCE, S ;
RUPNIAK, NMJ ;
STEVENTON, MJ ;
IVERSEN, SD .
NEUROLOGY, 1990, 40 (06) :927-933
[28]   Staging of brain pathology related to sporadic Parkinson's disease [J].
Braak, H ;
Del Tredici, K ;
Rüb, U ;
de Vos, RAI ;
Steur, ENHJ ;
Braak, E .
NEUROBIOLOGY OF AGING, 2003, 24 (02) :197-211
[29]   Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease [J].
Breidert, T ;
Callebert, J ;
Heneka, MT ;
Landreth, G ;
Launay, JM ;
Hirsch, EC .
JOURNAL OF NEUROCHEMISTRY, 2002, 82 (03) :615-624
[30]   CB1 cannabinoid receptor signalling in Parkinson's disease [J].
Brotchie, JM .
CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (01) :54-61
12345678910